Related Experiment Video
Updated: Jul 5, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Novel cytotoxic agents: epothilones
1The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. goodin@umdnj.edu
Purpose:
The epothilones are effective antitumor medications for patients with breast cancer, including patients who have been previously treated with or are resistant to anthracyclines or the taxanes.
Summary:
With the best currently available therapies, the median survival time for patients with metastatic breast cancer is only 2-3 years, and many patients develop resistance to taxanes or other chemotherapy drugs. The epothilones are a novel class of antitumor medications, similar to the taxanes in some respects, but that also possess several advantages. Like taxanes, epothilones are believed to produce antitumor effects by binding to and stabilizing intracellular microtubules, which are essential in DNA replication and cell division. Several in vitro and animal studies have shown that the epothilones are more potent microtubule stabilizers than the taxanes, they are effective against cancer cell lines with high levels of drug resistance, and they induce the regression of taxane-resistant human tumors. Preclinical studies also have demonstrated synergistic increases in tumor cell killing when the epothilones are combined with other antitumor medications. Epothilone B (patupilone) has been evaluated in a series of phase I and II clinical trials, which demonstrated disease stabilization or objective responses in patients with a variety of cancers, including ovarian, prostate, breast, colon, stomach, and kidney cancers. This agent is currently being evaluated in phase III clinical trials. A second epothilone, ixabepilone, was recently approved by the FDA for the treatment of metastatic breast cancer. Ixabepilone was evaluated as monotherapy for the treatment of breast cancer in phase II clinical trials of previously untreated patients and in taxane-experienced and taxane-resistant disease. A phase III clinical trial demonstrated that the combination of ixabepilone and capecitabine was superior to capecitabine alone in heavily pretreated, taxane-resistant patients.
Conclusion:
Ongoing clinical trials will continue to define the role of the epothilones in cancer therapy.
Insights
Epothilones are effective antitumor drugs for breast cancer, even with resistance to other treatments. Ongoing trials will further define their role in cancer therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic breast cancer has a poor prognosis, with limited survival even with current therapies.
- Drug resistance to taxanes and other chemotherapies is a significant challenge in treating metastatic breast cancer.
Purpose of the Study:
- To evaluate the efficacy of epothilones as antitumor medications for breast cancer patients.
- To explore the potential of epothilones in overcoming resistance to existing chemotherapy drugs like taxanes and anthracyclines.
Main Methods:
- Preclinical studies (in vitro and animal models) assessed epothilone's microtubule stabilizing effects and efficacy against resistant cancer cell lines.
- Clinical trials (Phase I, II, and III) evaluated epothilone B (patupilone) and ixabepilone in various cancers, including breast cancer.
- Phase III trials compared ixabepilone combined with capecitabine versus capecitabine alone in heavily pretreated, taxane-resistant patients.
Main Results:
- Epothilones demonstrate potent microtubule stabilization, exceeding that of taxanes.
- Epothilones show efficacy against cancer cell lines with high drug resistance and induce regression of taxane-resistant tumors.
- Epothilone B (patupilone) showed disease stabilization or objective responses in Phase I/II trials across multiple cancer types.
- Ixabepilone, as monotherapy, showed efficacy in Phase II trials for breast cancer, including taxane-resistant cases.
- A Phase III trial indicated that ixabepilone plus capecitabine was superior to capecitabine alone in taxane-resistant patients.
Conclusions:
- Epothilones represent a novel class of antitumor agents with advantages over taxanes, particularly in overcoming drug resistance.
- Ixabepilone is approved for metastatic breast cancer treatment and has shown promise in combination therapy.
- Further clinical trials are essential to fully establish the role of epothilones in comprehensive cancer treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:38Mitogens and the Cell Cycle
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...